Openbookopenbook
Equity
Faron Pharmaceuticals Oy(FARN)
GBX --+0.00%
Reward36Moderate
Risk82High
📊75%Data
Revenue down 87% YoY
FARN
+0.0 · +0.00%
GBX · LSE
Faron Pharmaceuticals Oy | Healthcare
Earnings Deterioration
Market Cap:221.89M
ℹ️
Reward Rating
36
Moderate
Bottom 5% (model universe)
75% data coverage
ℹ️
Risk Rating
82
High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on FARN to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: 1008p.

What is Faron Pharmaceuticals Oy?

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company.

FARN · Verdict

Limited reward · high risk

FARN has limited near-term tailwinds — cash flow and profitability weigh on the model output.

Based on 88% data coverage

FARN · Verdict

What’s working & what to watch

Watchouts 5

  • Cash flow5/100

    Weak vs peers

  • Profitability10/100

    -3962% return on equity

  • Balance sheet13/100

    Current ratio 1.09

  • Growth31/100

    Earnings -89.3% CAGR

  • Volatility35/100

    Below average

Model-based scoring. For information only — not financial advice.

What is Faron Pharmaceuticals Oy?

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. Its lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 221.89M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue growth is subdued, limiting near-term earnings expansion.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Elevated volatility implies higher downside and expectation risk.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (36)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are high — this profile reflects meaningful downside exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap221.89M
P/E RatioN/A
Dividend YieldN/A
52 Week High270
52 Week Low44
Last AnnualDecember
IPO DateN/A
IncorporatedUK
Shares Outstanding114M
No. of Employees32
IndustryBiotechnology
ExchangeLSE
Beta1.243
CurrencyGBX · Reports in EUR
Websitefaron.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.